The NIH Clinical Center intends to sole-source procure compounded piflufolastat F-18 (Pylarify) patient-ready unit doses from Progenics Pharmaceuticals Inc., the only local authorized nuclear pharmacy for Lantheus Medical Imaging’s product. The radiopharmaceutical is FDA-approved, US NRC-regulated, time-sensitive due to rapid decay, and must be compounded, dispensed, calibrated, and delivered daily for specific patients at the NIH Clinical Center. The IDIQ requirement includes 150–230 PYLARIFY piflufolastat F-18 injections and 4 unused-dose fees for a base year plus four option years. The base period of performance is 10/01/2026–09/30/2027, with option years extending through 09/30/2031. Performance/delivery is at the NIH Clinical Center in Bethesda, MD, and the action is sole-sourced under FAR authority, so interested responsible sources would need to demonstrate capability as an authorized provider.